Rafael pharmaceuticals announces positive preplanned interim futility analysis of pivotal phase 3 trial (armada 2000) of cpi-613® (devimistat) for relapsed or refractory acute myeloid leukemia (aml)

Cranbury, n.j., july 01, 2021 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive outcome from its preplanned interim futility analysis of its pivotal phase 3 trial (armada 2000) of cpi-613® (devimistat) for relapsed or refractory acute myeloid leukemia (aml) as determined by an independent data monitoring committee (idmc). the idmc met on friday, jun. 25 and based on the 142 within the intention to treat population, the trial was determined to be non-futile. the idmc recommended to continue the trial as is.
RFL Ratings Summary
RFL Quant Ranking